NCT05583357View on ClinicalTrials.gov

Exploratory Clinical Study to Evaluation of the Safety and Immunogenicity of Bivalent Vaccine V-01D-351

EARLY_PHASE1UnknownINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 15, 2022

Primary Completion Date

September 13, 2022

Study Completion Date

August 10, 2023

Conditions
COVID-19 Pandemic
Interventions
BIOLOGICAL

V-01D-351

One dose of V-01D-351 on participants received 2 doses of inactivated vaccine (CoronaVac) 6-15 months ago

BIOLOGICAL

V-01D-351

One dose of V-01D-351 on participants received 3 doses of inactivated vaccine (CoronaVac) 5-9 months ago

BIOLOGICAL

CoronaVac

One dose of CoronaVac on participants received 2 doses of inactivated vaccine (CoronaVac) 6-15 months ago

BIOLOGICAL

CoronaVac

One dose of CoronaVac on participants received 3 doses of inactivated vaccine (CoronaVac) 5-9 months ago

Trial Locations (1)

512000

Shaoguan Hospital of Chinese Medicine, Shaoguan

Sponsors
All Listed Sponsors
lead

Livzon Pharmaceutical Group Inc.

INDUSTRY